8 Most Oversold Strong Buy-Rated Stocks to Invest In

Page 2 of 2

6. Maze Therapeutics, Inc. (NASDAQ:MAZE)

On March 31, 2026, JPMorgan raised the price target on Maze Therapeutics, Inc. (NASDAQ:MAZE) to $58 from $52 and maintained an Overweight rating. JPMorgan cited a higher probability of success for MZE829 following Phase 2 data and said the drug appears “directionally better” in the focal segmental glomerulosclerosis population.

On March 25, 2026, H.C. Wainwright raised its price target on Maze Therapeutics, Inc. (NASDAQ:MAZE) to $110 from $60 and maintained a Buy rating, saying Phase 2 HORIZON data showed “unambiguously positive” efficacy in APOL1-mediated kidney disease. H.C. Wainwright added that MZE829 has a “best-in-class profile” and a “de-risked regulatory path.”

On March 25, 2026, Maze Therapeutics reported Q4 EPS of (65c), compared to the (78c) consensus estimate. Cash, cash equivalents, and marketable securities were $360.0 million as of December 31, 2025, compared to $196.8 million as of December 31, 2024, and the company expects its current cash position to fund operations into 2028. On the same day, the company announced positive topline data from the Phase 2 HORIZON trial, reporting a 35.6% mean reduction in proteinuria at week 12, with 50% of patients achieving more than a 30% reduction, and said it plans to continue enrollment and advance MZE829 into a pivotal program.

Maze Therapeutics, Inc. (NASDAQ:MAZE) develops small molecule precision medicines for kidney and metabolic diseases.

While we acknowledge the potential of MAZE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MAZE and that has 100x upside potential, check out our report about the cheapest AI stock.

Click to continue reading and see the 5 Most Oversold Strong Buy-Rated Stocks to Invest In.

Disclosure: None. Follow Insider Monkey on Google News.

Page 2 of 2